Skip to content
  • Home
  • About Us
    • Mission & Values
    • Leadership
  • Science
    • Technologies
    • Pipeline
    • Partnership
  • News
  • Home
  • About Us
    • Mission & Values
    • Leadership
  • Science
    • Technologies
    • Pipeline
    • Partnership
  • News
Contact Us
  • Home
  • About Us
    • Mission & Values
    • Leadership
  • Science
    • Technologies
    • Pipeline
    • Partnership
  • News
Contact Us

Publication Category: Strip

Splicing mutations in the CFTR gene as therapeutic targets

Karine Deletang1 and Magali Taulan-Cadars – Gene Therapy (2022) 29:399–406

miRNA repertoires of cystic fibrosis ex vivo models highlight miR-181a and miR-101 that regulate WISP1 expression

– Alexandra Pommier, Jessica Varilh, Solenne Bleuse, Karine Delétang, Jennifer Bonini, Anne Bergougnoux, Emmanuelle Brochiero, Michel Koenig, Mireille Claustres, Magali Taulan-Cadars

Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis

DOI: 10.1183/09031936.00113214 – Victoria Viart1,2,3, Anne Bergougnoux1,3, Jennifer Bonini1,2, Jessica Varilh1,3, Raphaël Chiron4, Olivier Tabary5,6, Nicolas Molinari7,8, Mireille Claustres1,2,3 and Magali Taulan-Cadars1,2.

Get in touch

Partner with us to
redefine
cystic fibrosis care.

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

Request Information
Investor Relations

Email

contact@aceso-therapeutics.com

Headquarters

Montpellier, France

Pioneering first-in-class dual-therapy approaches for Cystic Fibrosis patients underserved by today’s standard of care.

Company

  • Home
  • About Us
  • Science
  • News

Legal

  • Terms of use
  • Privacy
  • Terms
  • Cookies

Contact

  • contact@aceso-therapeutics.com
  • Montpellier, France

© 2026 ACESO Therapeutics. All rights reserved.

Designed for a future where every CF patient has a therapy.